JP6320382B2 - メラノーマの処置および診断 - Google Patents

メラノーマの処置および診断 Download PDF

Info

Publication number
JP6320382B2
JP6320382B2 JP2015527533A JP2015527533A JP6320382B2 JP 6320382 B2 JP6320382 B2 JP 6320382B2 JP 2015527533 A JP2015527533 A JP 2015527533A JP 2015527533 A JP2015527533 A JP 2015527533A JP 6320382 B2 JP6320382 B2 JP 6320382B2
Authority
JP
Japan
Prior art keywords
alkyl
cells
mir
cancer
melanoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015527533A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015532642A (ja
JP2015532642A5 (https=
Inventor
ソハイル タヴァズィ
ソハイル タヴァズィ
ノラ ジー． ペンチェヴァ
ノラ ジー． ペンチェヴァ
Original Assignee
ザ ロックフェラー ユニヴァーシティ
ザ ロックフェラー ユニヴァーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ロックフェラー ユニヴァーシティ, ザ ロックフェラー ユニヴァーシティ filed Critical ザ ロックフェラー ユニヴァーシティ
Publication of JP2015532642A publication Critical patent/JP2015532642A/ja
Publication of JP2015532642A5 publication Critical patent/JP2015532642A5/ja
Application granted granted Critical
Publication of JP6320382B2 publication Critical patent/JP6320382B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5751—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Emergency Medicine (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
JP2015527533A 2012-08-13 2013-08-13 メラノーマの処置および診断 Active JP6320382B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261682339P 2012-08-13 2012-08-13
US61/682,339 2012-08-13
US201361784057P 2013-03-14 2013-03-14
US61/784,057 2013-03-14
PCT/US2013/054690 WO2014028461A2 (en) 2012-08-13 2013-08-13 Treatment and diagnosis of melanoma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018023820A Division JP6523502B2 (ja) 2012-08-13 2018-02-14 メラノーマの処置および診断

Publications (3)

Publication Number Publication Date
JP2015532642A JP2015532642A (ja) 2015-11-12
JP2015532642A5 JP2015532642A5 (https=) 2016-09-29
JP6320382B2 true JP6320382B2 (ja) 2018-05-09

Family

ID=50101591

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2015527533A Active JP6320382B2 (ja) 2012-08-13 2013-08-13 メラノーマの処置および診断
JP2018023820A Active JP6523502B2 (ja) 2012-08-13 2018-02-14 メラノーマの処置および診断
JP2019083874A Active JP7005551B2 (ja) 2012-08-13 2019-04-25 メラノーマの処置および診断
JP2021105207A Active JP7472080B2 (ja) 2012-08-13 2021-06-24 メラノーマの処置および診断
JP2023223727A Pending JP2024041827A (ja) 2012-08-13 2023-12-28 メラノーマの処置および診断
JP2026001136A Pending JP2026062949A (ja) 2012-08-13 2026-01-06 メラノーマの処置および診断

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2018023820A Active JP6523502B2 (ja) 2012-08-13 2018-02-14 メラノーマの処置および診断
JP2019083874A Active JP7005551B2 (ja) 2012-08-13 2019-04-25 メラノーマの処置および診断
JP2021105207A Active JP7472080B2 (ja) 2012-08-13 2021-06-24 メラノーマの処置および診断
JP2023223727A Pending JP2024041827A (ja) 2012-08-13 2023-12-28 メラノーマの処置および診断
JP2026001136A Pending JP2026062949A (ja) 2012-08-13 2026-01-06 メラノーマの処置および診断

Country Status (10)

Country Link
US (8) US9399028B2 (https=)
EP (3) EP3626309B1 (https=)
JP (6) JP6320382B2 (https=)
CN (3) CN116271053A (https=)
AU (4) AU2013302861A1 (https=)
CA (2) CA3211094A1 (https=)
DK (1) DK2882496T3 (https=)
ES (2) ES2941477T3 (https=)
HU (1) HUE046292T2 (https=)
WO (1) WO2014028461A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022001571A (ja) * 2012-08-13 2022-01-06 ザ ロックフェラー ユニヴァーシティ メラノーマの処置および診断

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0913578A2 (pt) 2008-05-14 2017-06-06 Dermtech Int diagnose de melanoma e lentigo solar por análise de ácido nucléico
DK2820013T3 (en) 2012-03-02 2018-10-29 Ralexar Therapeutics Inc Liver X Receptor (LXR) modulators for the treatment of dermal diseases, disorders and conditions
PT3041835T (pt) 2013-09-04 2020-07-13 Ellora Therapeutics Inc Moduladores de recetor de fígado x (lxr)
JP2016532713A (ja) 2013-09-04 2016-10-20 アレクサー セラピューティクス， インク． 肝臓ｘ受容体（ｌｘｒ）調節因子
US10669296B2 (en) 2014-01-10 2020-06-02 Rgenix, Inc. LXR agonists and uses thereof
WO2019161126A1 (en) 2018-02-14 2019-08-22 Dermtech, Inc. Novel gene classifiers and uses thereof in non-melanoma skin cancers
WO2016100619A2 (en) * 2014-12-17 2016-06-23 Rgenix, Inc. Treatment and diagnosis of cancer
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
US10709428B2 (en) 2015-05-01 2020-07-14 Dermtech, Inc. Non-invasive skin collection system
US11802305B2 (en) * 2015-06-24 2023-10-31 Oxford BioDynamics PLC Detection processes using sites of chromosome interaction
US20200046671A1 (en) * 2015-06-29 2020-02-13 Regents Of The University Of Minnesota Apobec3b mutagenesis and immunotherapy
JP2018527895A (ja) 2015-06-29 2018-09-27 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 抗−ａｐｏｂｅｃ３抗体並びにその製造及び使用方法
CA3010883A1 (en) * 2016-01-11 2017-07-20 The Rockefeller University Methods for the treatment of myeloid derived suppressor cells related disorders
WO2017142988A1 (en) 2016-02-18 2017-08-24 The Wistar Institute Of Anatomy And Biology Methods and compositions for treating melanoma
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI755395B (zh) * 2016-05-13 2022-02-21 美商再生元醫藥公司 抗-pd-1抗體與輻射治療癌症之組合
WO2018013534A1 (en) * 2016-07-11 2018-01-18 Dana-Farber Cancer Institute, Inc. Methods for treating pten deficient epithelial cancers using a combination of anti-pi3kbeta and anti-immune checkpoint agents
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
CN110494415A (zh) * 2017-03-03 2019-11-22 睿治尼斯公司 具有改善的稳定性的制剂
CN106890315B (zh) * 2017-03-16 2019-09-06 北京热休生物技术有限公司 Apo-e蛋白及其多肽在治疗与预防癌症中的应用
AU2018269982B2 (en) * 2017-05-16 2024-06-13 Biomed Valley Discoveries, Inc. Compositions and methods for treating cancer with atypical BRAF mutations
EP3713575A4 (en) 2017-11-21 2021-08-25 Rgenix, Inc. POLYMORPHS AND THEIR USES
JP7616995B2 (ja) * 2018-11-28 2025-01-17 プリベイル セラピューティクス，インコーポレーテッド 神経変性疾患のための遺伝子治療
AU2020228660A1 (en) * 2019-02-28 2021-08-26 Inspirna, Inc. APOE genotyping in cancer prognostics and treatment
WO2020198229A1 (en) 2019-03-26 2020-10-01 Dermtech, Inc. Novel gene classifiers and uses thereof in skin cancers
WO2020222858A1 (en) * 2019-04-27 2020-11-05 Ocugen, Inc. Adeno-associated virus vector mediated gene therapy for ophthalmic diseases
CN110218235B (zh) * 2019-05-09 2020-09-25 中山大学 一种化合物及其制备方法和作为荧光偏振探针在LXRβ配体筛选中的应用
AU2020345791A1 (en) * 2019-09-11 2022-03-31 Inspirna, Inc. Methods of treating cancer
WO2021062157A1 (en) * 2019-09-27 2021-04-01 The Rockefeller University Compositions and methods for treating metastatic gastrointestinal cancer
RU2716811C1 (ru) * 2019-11-14 2020-03-16 федеральное государственное бюджетное образовательное учреждение высшего образования "Новгородский государственный университет имени Ярослава Мудрого" Способ ранней диагностики поверхностно распространяющихся меланом
HUE067466T2 (hu) 2019-12-13 2024-10-28 Inspirna Inc Fémsók és alkalmazásuk
EP4081302A4 (en) 2019-12-23 2025-01-29 University Of Massachusetts OLIGONUCLEOTIDES FOR TISSUE-SPECIFIC GENE EXPRESSION MODULATION
US20240101640A1 (en) * 2020-08-21 2024-03-28 Csl Behring Ag Cd91 polypeptide for use in detecting hemopexin:heme complex
US20250075217A1 (en) * 2021-07-30 2025-03-06 Alnylam Pharmaceuticals, Inc. Peptide ligands for cns and ocular delivery of rnai compounds
CN114276999A (zh) * 2022-03-03 2022-04-05 中日友好医院(中日友好临床医学研究所) 黑素瘤细胞株及其制备方法

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5676978A (en) 1989-02-14 1997-10-14 Amira, Inc. Methods of inhibiting undesirable cell growth using a combination of a cyclocreatine compound and a hyperplastic inhibitory agent
US5324731A (en) 1989-02-14 1994-06-28 Amira, Inc. Method of inhibiting transformation of cells in which purine metabolic enzyme activity is elevated
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5215882A (en) 1989-11-30 1993-06-01 Ortho Diagnostic Systems, Inc. Method of immobilizing nucleic acid on a solid surface for use in nucleic acid hybridization assays
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5837832A (en) 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
DE69621507T2 (de) 1995-03-28 2003-01-09 Japan Science And Technology Corp., Kawaguchi Verfahren zur molekularen Indexierung von Genen unter Verwendung von Restriktionsenzymen
US5843974A (en) * 1995-06-06 1998-12-01 Eli Lilly And Company Methods of inhibiting melanoma using Benzothiophenes as cytotoxic agents per se
US5958342A (en) 1996-05-17 1999-09-28 Incyte Pharmaceuticals, Inc. Jet droplet device
US6060240A (en) 1996-12-13 2000-05-09 Arcaris, Inc. Methods for measuring relative amounts of nucleic acids in a complex mixture and retrieval of specific sequences therefrom
US6090556A (en) 1997-04-07 2000-07-18 Japan Science & Technology Corporation Method for quantitatively determining the expression of a gene
US5994076A (en) 1997-05-21 1999-11-30 Clontech Laboratories, Inc. Methods of assaying differential expression
CA2314397C (en) 1997-12-12 2010-04-13 University Of Western Ontario Novel peptide, apoep1.b, compositions and uses thereof
US6004755A (en) 1998-04-07 1999-12-21 Incyte Pharmaceuticals, Inc. Quantitative microarray hybridizaton assays
US6048695A (en) 1998-05-04 2000-04-11 Baylor College Of Medicine Chemically modified nucleic acids and methods for coupling nucleic acids to solid support
US6087112A (en) 1998-12-30 2000-07-11 Oligos Etc. Inc. Arrays with modified oligonucleotide and polynucleotide compositions
US6316503B1 (en) 1999-03-15 2001-11-13 Tularik Inc. LXR modulators
US8257750B2 (en) 1999-04-30 2012-09-04 Kibow Biotech, Inc. Calcium carbonate compositions for preventing or treating hyperphosphatemia
AU2001280576A1 (en) 2000-07-18 2002-01-30 Uab Research Foundation Tissue-specific self-inactivating gene therapy vector
US20030027335A1 (en) 2000-09-07 2003-02-06 Ruley H. Earl Genome engineering by cell-permeable DNA site-specific recombinases
JP2004509161A (ja) 2000-09-18 2004-03-25 グラクソ　グループ　リミテッド Ｌｘｒのアゴニストとして有用な置換アミノプロポキシアリール誘導体
AU2002219718A1 (en) 2000-12-13 2002-06-24 Sca Hygiene Products Zeist B.V. Process for oxidising primary alcohols
JP2003033179A (ja) 2001-07-05 2003-02-04 Asahi Kasei Corp 可逆的遺伝子導入ベクター
EP1487776A4 (en) * 2002-03-27 2005-05-25 Smithkline Beecham Corp ACID COMPOUNDS AND ESTERS AND METHODS OF USE THEREOF
AU2003226094A1 (en) 2002-03-27 2003-10-13 Smithkline Beecham Corporation Compounds and methods
US7247748B2 (en) 2002-03-27 2007-07-24 Smithkline Corporation Amide compounds and methods of using the same
WO2004009765A2 (en) 2002-07-19 2004-01-29 Althea Technologies, Inc. Strategies for gene expression analysis
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
WO2004078939A2 (en) 2003-03-03 2004-09-16 University Of Massachusetts REGULATION OF Mdm2 FUNCTION
US20050130919A1 (en) 2003-07-18 2005-06-16 University Of Massachusetts Regulatable promoters for synthesis of small hairpin RNA
WO2005039643A2 (en) 2003-10-20 2005-05-06 Nsgene A/S In vivo gene therapy of parkinson's disease
RU2006124843A (ru) 2003-12-12 2008-01-20 Уайт (Us) Хинолины, пригодные для лечения сердечно-сосудистого заболевания
FR2865736B1 (fr) 2004-02-02 2006-07-14 Synt Em Inhibiteurs de l'angiogenese, compositions les contenant et leur utilisation pour le traitement des maladies liees a une deregulation de l'angiogenese
US20050289659A1 (en) 2004-05-18 2005-12-29 Jacks E T Cre-lox based method for conditional RNA interference
US20080255111A1 (en) * 2004-07-02 2008-10-16 Sankyo Company Limited Tissue Factor Production Inhibitor
AU2005272043B2 (en) 2004-07-07 2010-07-29 Merck Sharp & Dohme Corp. Pyrazole amide derivatives, compositions containing such compounds and methods of use
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
JP4620123B2 (ja) 2004-10-01 2011-01-26 エフ．ホフマン−ラ ロシュ アーゲー ヘキサフルオロイソプロパノール置換エーテル誘導体
JP4644714B2 (ja) 2004-12-22 2011-03-02 エフ．ホフマン−ラ ロシュ アーゲー 新規なシクロヘキサン誘導体
SE0500056D0 (sv) 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 4
CA2592771A1 (en) 2005-01-10 2006-07-13 Astrazeneca Ab Derivatives of isothiazol-3(2h)-one 1,1-dioxides as liver x receptor modulators
SE0500058D0 (sv) 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 5
SE0500055D0 (sv) 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 3
WO2006073364A1 (en) 2005-01-10 2006-07-13 Astrazeneca Ab Derivatives of isothiazol-3 (2h)-thione 1,1-dioxides as liver x receptor modulators
BRPI0607404A2 (pt) 2005-03-01 2009-09-01 Wyeth Corp compostos de cinolina e seu uso como moduladores de receptor de x hepático
US8318760B2 (en) 2005-03-21 2012-11-27 Merck Sharp & Dohme Corp. Substituted aryl and heteroaryl derivatives, compositions containing such compounds and methods of use
US8703805B2 (en) 2005-06-27 2014-04-22 Exelixis Patent Company Llc Modulators of LXR
HRP20110498T1 (hr) 2005-10-07 2011-08-31 Exelixis Azetidini kao inhibitori mek za liječenje proliferativnih bolesti
US7790745B2 (en) 2005-10-21 2010-09-07 Bristol-Myers Squibb Company Tetrahydroisoquinoline LXR Modulators
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
RU2008123388A (ru) 2005-11-14 2009-12-27 Айрм Ллк (Bm) Соединения и композиции в качестве модуляторов lxr
WO2007081335A1 (en) 2006-01-12 2007-07-19 Merck & Co., Inc. Therapeutic compounds for treating dyslipidemic conditions
WO2007108749A1 (en) 2006-03-20 2007-09-27 Cepep Iii Ab Chimeric constructs between cancer-homing peptides and cell-penetrating peptides coupled to anticancer drugs and/or diagnostic agent/agents
US20100048944A1 (en) * 2006-07-19 2010-02-25 Farhad Parhami Interactions of hedgehog and liver x receptor signaling pathways
TW200825054A (en) 2006-10-18 2008-06-16 Wyeth Corp Quinoline compounds
US8324367B2 (en) 2006-11-03 2012-12-04 Medtronic, Inc. Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
ES2380499T3 (es) 2006-11-30 2012-05-14 Kowa Company. Ltd. Compuesto de Carbinol sustituido
KR20090094125A (ko) 2006-12-08 2009-09-03 엑셀리시스, 인코포레이티드 Ｌｘｒ 및 ｆｘｒ 조절자
JP2008179562A (ja) 2007-01-24 2008-08-07 Kowa Co Ｌｘｒアゴニスト
US8993628B2 (en) 2007-02-23 2015-03-31 City Of Hope Synthetic ligands selective for LXRβ over LXRα, identification and methods of use thereof
BRPI0811091A8 (pt) 2007-05-18 2015-09-29 Wyeth Corp Composto, composição farmacêutica, métodos para prevenir ou tratar uma doença, distúrbio ou condição, para aumentar níveis de colesterol hdl no soro em um indivíduo, para reduzir níveis de colestetol ldl no soro em um indivíduo, para aumentar o transporte invertido de colesterol em um indivíduo, e para reduzir a absorção do colesterol em um indivíduo, e, uso de um composto
EP3443976A1 (en) 2007-06-29 2019-02-20 Sarepta Therapeutics, Inc. Tissue specific peptide conjugates and methods
MX2010001742A (es) 2007-08-13 2010-03-10 Hoffmann La Roche Nuevos derivados de piperazina-amida.
TW200922582A (en) 2007-08-20 2009-06-01 Organon Nv N-benzyl, N'-arylcarbonylpiperazine derivatives
US8039493B2 (en) 2007-09-27 2011-10-18 Hoffmann-La Roche Inc. Biaryl sulfonamide derivatives
EP2623599B1 (en) * 2007-10-04 2019-01-02 Roche Innovation Center Copenhagen A/S Micromirs
ES2572356T3 (es) 2007-11-09 2016-05-31 Peregrine Pharmaceuticals Inc Composiciones de anticuerpos dirigidos contra VEGF y procedimientos
US8236753B2 (en) * 2007-12-10 2012-08-07 The Brigham And Women's Hospital, Inc. RAP variants for drug delivery and methods of use thereof
AU2008345681A1 (en) 2007-12-21 2009-07-09 Wyeth Llc Imidazo [1,2-a] pyridine compounds
US20110034526A1 (en) 2007-12-21 2011-02-10 Wyeth Llc Benzimidazole Compounds
US20100331333A1 (en) 2007-12-21 2010-12-30 Wyeth Llc Imidazo [1,2-B] Pyridazine Compounds
CN101952293A (zh) 2007-12-21 2011-01-19 惠氏有限责任公司 吡唑并[1,5-a]嘧啶化合物
US7919509B2 (en) 2008-02-29 2011-04-05 Kowa Company, Ltd. 2-oxochromene derivatives
EP2286220A2 (en) * 2008-05-29 2011-02-23 Bristol-Myers Squibb Company Methods for predicting patient response to modulation of the co-stimulatory pathway
JP5706818B2 (ja) * 2008-07-01 2015-04-22 コグノッシ， インコーポレイテッド ＡｐｏＥペプチドにより癌を治療する方法
KR101814408B1 (ko) 2008-09-26 2018-01-04 다나-파버 캔서 인스티튜트 인크. 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도
US20120156216A1 (en) * 2009-03-02 2012-06-21 Youngman Oh Methods and Compositions for Treatment of Tumor Metastasis
KR101676704B1 (ko) * 2009-05-28 2016-11-16 엑셀리시스 페이턴트 컴퍼니 엘엘씨 Ｌｘｒ 조절자
WO2011115892A1 (en) * 2010-03-15 2011-09-22 Griffin Patrick R Modulators of the retinoic acid receptor-related orphan receptors
WO2011130426A2 (en) * 2010-04-13 2011-10-20 New York University Compositions and methods for treatment of melanoma
EP2584045A4 (en) 2010-06-16 2013-12-04 Nat Univ Corp Hamamatsu METHOD FOR DETECTING COLORECTAL CANCER
EP2474617A1 (en) * 2011-01-11 2012-07-11 InteRNA Technologies BV Mir for treating neo-angiogenesis
US20130004481A1 (en) * 2011-01-12 2013-01-03 Boehringer Ingelheim International Gmbh Anticancer therapy
TW201242953A (en) 2011-03-25 2012-11-01 Bristol Myers Squibb Co Imidazole prodrug LXR modulators
WO2013043569A1 (en) * 2011-09-20 2013-03-28 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
EP3626309B1 (en) * 2012-08-13 2023-03-08 The Rockefeller University Lxrbeta agonist for the treatment of cancer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022001571A (ja) * 2012-08-13 2022-01-06 ザ ロックフェラー ユニヴァーシティ メラノーマの処置および診断

Also Published As

Publication number Publication date
ES2765573T3 (es) 2020-06-09
AU2013302861A1 (en) 2015-03-05
US11865094B2 (en) 2024-01-09
JP2018140982A (ja) 2018-09-13
US20160331726A1 (en) 2016-11-17
CA2882292C (en) 2023-10-17
CN104780976A (zh) 2015-07-15
US20150023955A1 (en) 2015-01-22
JP2015532642A (ja) 2015-11-12
US10945978B2 (en) 2021-03-16
AU2020200715A1 (en) 2020-02-20
CN110037999B (zh) 2023-01-13
US20170319525A1 (en) 2017-11-09
AU2020200715B2 (en) 2022-05-12
EP4218935A1 (en) 2023-08-02
US9399028B2 (en) 2016-07-26
US20200230090A1 (en) 2020-07-23
US9707195B2 (en) 2017-07-18
CN116271053A (zh) 2023-06-23
ES2941477T3 (es) 2023-05-23
US9962348B2 (en) 2018-05-08
HK1212273A1 (zh) 2016-06-10
JP2024041827A (ja) 2024-03-27
CA2882292A1 (en) 2014-02-20
EP3626309B1 (en) 2023-03-08
US20180153833A1 (en) 2018-06-07
EP2882496B1 (en) 2019-10-09
DK2882496T3 (da) 2019-11-11
EP2882496A2 (en) 2015-06-17
AU2022215282A1 (en) 2022-11-03
JP2022001571A (ja) 2022-01-06
AU2018226488B2 (en) 2020-01-23
JP6523502B2 (ja) 2019-06-05
US20210220306A1 (en) 2021-07-22
US10543183B2 (en) 2020-01-28
CA3211094A1 (en) 2014-02-20
HUE046292T2 (hu) 2020-02-28
US20240252458A1 (en) 2024-08-01
US20150073053A1 (en) 2015-03-12
CN104780976B (zh) 2019-01-01
EP3626309A1 (en) 2020-03-25
JP2019151646A (ja) 2019-09-12
JP7005551B2 (ja) 2022-02-04
WO2014028461A3 (en) 2014-04-17
US12502368B2 (en) 2025-12-23
CN110037999A (zh) 2019-07-23
JP2026062949A (ja) 2026-04-10
JP7472080B2 (ja) 2024-04-22
AU2018226488A1 (en) 2018-09-27
US9526710B2 (en) 2016-12-27
WO2014028461A2 (en) 2014-02-20
EP2882496A4 (en) 2016-07-06

Similar Documents

Publication Publication Date Title
JP7005551B2 (ja) メラノーマの処置および診断
HK40095822A (zh) 治疗和诊断黑素瘤
HK40005229B (en) Treatment and diagnosis of melanoma
HK40005229A (en) Treatment and diagnosis of melanoma
HK1212273B (zh) 治疗和诊断黑素瘤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160810

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160810

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170606

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170906

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180214

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180306

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180403

R150 Certificate of patent or registration of utility model

Ref document number: 6320382

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250